Clinical Efficacy of Imeglimin (Twymeeg) for Elderly Patient with Type 2 Diabetes Mellitus (T2DM)

Abstract

Background: As an oral hypoglycaemic agent (OHA), imeglimin (Twymeeg) has been recently introduced to clinical practice for patients with type 2 diabetes mellitus (T2DM) as Twymeeg. It has beneficial pharmacological mechanisms, which are improving insulin secretion, increasing insulin sensitivity, and decreasing insulin resistance. Case Presentation: The case is 84-year-old man with mild cognitive impairment (MCI) for 3 years. He visited late August, 2021 our clinic for general malaise and was pointed out to have post-prandial blood glucose 336 mg/dL and HbA1c 8.6%. He was diagnosed with T2DM. Results: He was started to be given imeglimin 1000mg twice a day, and then HbA1c value was decreased to 7.3% in 4 weeks and 5.7% in 8 weeks. During 9-12 weeks, he felt loss of appetite and reduced food intake. Biochemical examination on 12 weeks showed decreased values of TP, Alb, HbA1c, glucose, free T3, and normal values of TSH, free T4. Doses of imeglimin were 500 mg twice a day for 9-12 weeks and discontinued after 12 weeks. Discussion: Regarding appetite loss, possible causes may include MCI, previous history of gallbladder dyskinesia, adverse effect of imeglimin, and so on. Further development of research will be expected for imeglimin in the future.

Elderly Female of Type 2 Diabetes (T2D) and Dementia with Clinical Improvement by Imeglimin (Twymeeg)

“…Recent OHAs include sodium-glucose cotransporter 2 inhibitor (SGLT2i) and oral administration of glucagon-like-peptide 1 receptor agonist (GLP1-RA) [4]. Furthermore, the latest novel OHA is imeglimin (Twemeeg) that shows dual efficacy of increasing insulin secretion and decreasing insulin resistance [5,6]. The characteristic point of imeglimin includes the similarity of molecules with metformin [7].…”

Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy

“…The authors' diabetic research group has been reporting for a long time, covering areas such as Carbo-70g breakfast loading, meal tolerance test (MTT), low carbohydrate diet (LCD), and various cases with continuous glucose monitoring (CGM) and OHAs [14,15]. Among their recent reports, pharmacological efficacy of imeglimin (Twymeeg) has been introduced [16]. Furthermore, the annual seasonal changes of HbA1c were analyzed for many cases of T2D [17,18].…”

CT Image of Consolidation and Ground-Glass Opacification (GGO) of COVID-19 in Diabetic Patient

“…fields such as type 1 and 2 diabetes (T1D, T2D), lowcarbohydrate diets (LCDs), meal tolerance tests (MTTs), continuous glucose monitoring (CGM), and others [9,10]. Some reports have discussed the novel OHA, imeglimin (Twymeeg) [11,12].…”